TRPV4 and glycogen storage disease VI: Most interestingly, TRPV4 was also proposed as a promising therapeutic target, and blocking TRPV4 may be a feasible approach to the the recent coronavirus disease 2019 (COVID-19) pandemic by protecting the alveolo-capillary barrier of the lungs from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) [79].